Research progress of autoimmune glial fibrillary acidic protein astrocytopathy

Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever,...

Full description

Bibliographic Details
Main Authors: WANG Wen⁃wen, LI Mei
Format: Article
Language:English
Published: Tianjin Huanhu Hospital 2022-03-01
Series:Chinese Journal of Contemporary Neurology and Neurosurgery
Subjects:
Online Access:http://www.cjcnn.org/index.php/cjcnn/article/view/2476
_version_ 1819157006661976064
author WANG Wen⁃wen
LI Mei
author_facet WANG Wen⁃wen
LI Mei
author_sort WANG Wen⁃wen
collection DOAJ
description Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.
first_indexed 2024-12-22T16:01:54Z
format Article
id doaj.art-bee9bce7a2d14cb2815cfcc821cb1569
institution Directory Open Access Journal
issn 1672-6731
language English
last_indexed 2024-12-22T16:01:54Z
publishDate 2022-03-01
publisher Tianjin Huanhu Hospital
record_format Article
series Chinese Journal of Contemporary Neurology and Neurosurgery
spelling doaj.art-bee9bce7a2d14cb2815cfcc821cb15692022-12-21T18:20:41ZengTianjin Huanhu HospitalChinese Journal of Contemporary Neurology and Neurosurgery1672-67312022-03-0122320521010.3969/j.issn.1672⁃6731.2022.03.014Research progress of autoimmune glial fibrillary acidic protein astrocytopathyWANG Wen⁃wen0 LI Mei1Department of Neurology, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, ChinaDepartment of Neurology, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, ChinaAutoimmune glial fibrillary acidic protein astrocytopathy (GFAP ⁃ A) is a novel autoimmune inflammatory disease of the central nervous system first reported in 2016. The predominant clinical syndrome of GFAP ⁃A is one or more of meningitis, encephalitis and myelitis. The initial symptoms are fever, headache, disturbance of consciousness and positive meningeal irritation. However, the pathogenesis of GFAP ⁃ A is unknown and there are no uniform diagnostic criteria for it. At present, it is generally accepted that positive glial fibrillary acidic protein ⁃immunoglobulin G (GFAP ⁃ IgG) in serum and cerebrospinal fluid (CSF) is the diagnostic standard. The positive predictive value of GFAP ⁃ IgG in CSF is higher than that in serum. Cell ⁃ based assay (CBA) and tissue ⁃ based assay (TBA) are both recommended methods for detecting GFAP ⁃ IgG. GFAP ⁃ IgG positive in serum and/or CSF is used to distinguish it from other autoimmune diseases in central nervous system, intracranial inflammatory and neoplastic disease. Most patients respond well to steroid therapy although a small number of patients may leave sequelae or relapse. This paper makes a systematic review on the etiology, pathogenesis, clinical features, diagnosis, differential diagnosis, treatment and prognosis of this disease, hoping that this review can deepen clinicians' understanding of the disease, discover and treat the disease in time.http://www.cjcnn.org/index.php/cjcnn/article/view/2476autoimmune diseases of the nervous systemglial fibrillary acidic proteinastrocytesreview
spellingShingle WANG Wen⁃wen
LI Mei
Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
Chinese Journal of Contemporary Neurology and Neurosurgery
autoimmune diseases of the nervous system
glial fibrillary acidic protein
astrocytes
review
title Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
title_full Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
title_fullStr Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
title_full_unstemmed Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
title_short Research progress of autoimmune glial fibrillary acidic protein astrocytopathy
title_sort research progress of autoimmune glial fibrillary acidic protein astrocytopathy
topic autoimmune diseases of the nervous system
glial fibrillary acidic protein
astrocytes
review
url http://www.cjcnn.org/index.php/cjcnn/article/view/2476
work_keys_str_mv AT wangwenwen researchprogressofautoimmuneglialfibrillaryacidicproteinastrocytopathy
AT limei researchprogressofautoimmuneglialfibrillaryacidicproteinastrocytopathy